Back Hepatitis C

Hepatitis C

FDA Approves Daclatasvir + Sofosbuvir for Hard-to-Treat Hepatitis C Patients

The U.S. Food and Drug Administration (FDA) this month approved an expanded indication for Bristol-Myers Squibb's daclatasvir (Daklinza) and Gilead Sciences sofosbuvir (Sovaldi) for additional patient groups including people with HIV/HCV coinfection, patients with advanced liver cirrhosis, and liver transplant recipients.

alt

AASLD 2015: MiR-122 Inhibitor RG-101 Suppresses Hepatitis C Virus with Single Dose

A single injection of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, reduced hepatitis C virus (HCV) levels by more than 4 log in people with HCV genotypes 1, 3, and 4, and 21% of treated patients still had undetectable virus levels 28 weeks after dosing, according to research presented at the AASLD Liver Meeting in November.

alt

AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate

An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of non-cirrhotic hepatitis C patients with HCV genotypes 1, 2, or 3, according to late-breaking research presented at the AASLD Liver Meeting in November.

alt

FDA Approves Zepatier (Grazoprevir/Elbasvir) for Hepatitis C Genotypes 1 and 4

The U.S. Food and Drug Administration (FDA) this week announced its approval of Merck's Zepatier -- a once-daily coformulation containing the hepatitis C virus (HCV) protease inhibitor grazoprevir and NS5A inhibitor elbasvir -- for the treatment of HCV genotypes 1 and 4. In several Phase 3 studies grazoprevir/elbasvir taken for 12 weeks demonstrated cure rates exceeding 90% for various groups including people with liver cirrhosis, HIV/HCV coinfected patients, and people who inject drugs.

alt

New Drugs Could Halt U.S. Hepatitis C Epidemic, but Only with Increased Testing and Treatment

Treatment using direct-acting antiviral agents (DAAs) could have a major impact on the hepatitis C virus (HCV) epidemic in the U.S., according to a model published in the November 30 online edition of Clinical Infectious Diseases. A 4-fold increase in treatment rates could prevent over a quarter of a million HCV-related deaths by 2040, and prevalence could be reduced by 90% with the scale up of screening efforts, especially targeting people who inject drugs (PWID). But the investigators caution that elimination of the epidemic with DAAs would require near-universal testing and a 20% annual treatment rate.

alt

AbbVie Opens Global Phase 3 Studies of ABT-493/ABT-530 Hepatitis C Regimen

AbbVie has started enrollment of a projected 1600 participants in 6 new international Phase 3 clinical trials evaluating a once-daily regimen of its investigational NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 for people with hepatitis C virus (HCV) genotypes 1 through 6, the company recently announced.

alt

Hepatitis C Linked to Increased Risk of Parkinson's Disease, Studies Show

People with hepatitis C virus (HCV) infection may be more likely to develop Parkinson's disease, especially when combined with other risk factors, though the reason for the association is not fully understood, according to a pair of recently published studies from Taiwan.

alt

Cardiovascular Disease Risk Is Higher for People with Hepatitis C

People with hepatitis C are at higher risk of dying from cardiovascular disease, having a stroke, or developing other cardiovascular problems than people with similar risk factors for heart disease who do not have hepatitis C, a meta-analysis of published studies has shown. The findings, published in the January 2016 edition of Gastroenterology, come from a meta-analysis of 22 epidemiological studies conducted in Italy.

alt

3. Better Options for Treating HCV Genotype 3 and Advanced Liver Disease

This year saw the emergence of new and better treatment options for people with hepatitis C virus (HCV) genotypes other than 1 and for those with advanced liver disease.

alt